GlassScriptPhysician profile
Daniel M Gonzalez
NPI 1861998650
$8,795.44
in general payments reported to CMS, 2019-2025
13 companies · $4,469 in 2025
The $4,469 reported for 2025 was more than what 97% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.40 · 2023: $3,983 · 2024: $324 · 2025: $4,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,229 · Food and Beverage: $2,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,228.72 |
| Food and Beverage | $2,548.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $2,179.65 | 2024-2025 | Sprint Pns System |
| Pacira Pharmaceuticals Incorporated | $2,094.29 | 2022-2025 | Iovera, Zilretta, Exparel |
| Evolution Surgical, INC | $1,950.46 | 2023-2025 | |
| Trice Medical, INC. | $1,469.65 | 2023 | |
| Arthrex, INC. | $754.54 | 2023-2025 | |
| Hydrocision, INC. | $86.69 | 2024-2025 | Tenjet |
| Fidia Pharma USA INC. | $62.06 | 2023-2025 | Triluron, Hymovis |
| Curonix LLC | $48.69 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Bioventus LLC | $43.76 | 2023 | Durolane |
| Depuy Synthes Sales INC. | $35.42 | 2023-2024 | Orthovisc, Monovisc |
| Si-Bone, INC. | $27.49 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $24.33 | 2024 | |
| Amgen INC. | $18.41 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.